A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Accent Therapeutics
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
University of Colorado, Denver
GlaxoSmithKline
University of Nebraska
Novartis
Institut du Cancer de Montpellier - Val d'Aurelle
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Sahlgrenska University Hospital
Elicio Therapeutics
Institut Bergonié
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Tempus AI
Stanford University